Related Experiment Video

Updated: Jan 16, 2026

The Isolation and Culture of Primary Epicardial Cells Derived from Human Adult and Fetal Heart Specimens
08:57

The Isolation and Culture of Primary Epicardial Cells Derived from Human Adult and Fetal Heart Specimens

Published on: April 24, 2018

8.2K

The Application of Epicardium in Heart Failure Treatment: Opportunities and Challenges

Chenlei Zhou1, Yaping Xu2, Zhikun Guo1,2

  • 1Henan Key Laboratory of Medical Tissue Regeneration, Xinxiang Medical University, Henan, P.R. China.

International Journal of Medical Sciences
|October 6, 2025
PubMed

Insights

Epicardium-derived cells (EPDCs) offer a promising regenerative approach for heart failure, addressing limitations of current treatments. This review explores their potential in cardiac repair and future therapeutic strategies.

Area of Science:

  • Regenerative Medicine
  • Cardiovascular Biology

Background:

  • Heart failure is a major global health burden with limited treatment options.
  • Current therapies like drugs, devices (LVAD, ICD), and transplantation have significant drawbacks, including resistance, complications, and donor scarcity.

Purpose of the Study:

  • To review the role of the epicardium and epicardium-derived cells (EPDCs) in cardiac regeneration.
  • To evaluate the application of epicardial-based therapies for heart failure management.
  • To discuss the translational potential and challenges of these novel strategies.

Main Methods:

  • Literature review focusing on epicardium anatomy, EPDC functions, and regenerative mechanisms.
  • Analysis of current and emerging epicardial-based therapeutic approaches.
  • Evaluation of clinical translation hurdles and future directions.

Main Results:

  • The epicardium and EPDCs play a crucial role in cardiac repair and regeneration.
  • EPDCs can be utilized via direct cell therapy, biomaterials, and gene therapy for heart repair.
  • Epicardial-based strategies show significant promise as an alternative to conventional heart failure treatments.

Conclusions:

  • Epicardial-based cell therapies represent a novel and promising avenue for managing heart failure.
  • Further research and development are needed to overcome translational challenges and optimize therapeutic efficacy.
  • Harnessing the regenerative potential of EPDCs could revolutionize heart failure treatment.

More Related Videos

In Vitro Culture of Epicardial Cells From Mouse Embryonic Heart06:31

In Vitro Culture of Epicardial Cells From Mouse Embryonic Heart

Published on: April 27, 2016

7.7K
Epicardial Outgrowth Culture Assay and Ex Vivo Assessment of Epicardial-derived Cell Migration07:44

Epicardial Outgrowth Culture Assay and Ex Vivo Assessment of Epicardial-derived Cell Migration

Published on: March 18, 2016

8.6K

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
468
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
255
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
338
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
319
Layers of the Heart Wall01:15

Layers of the Heart Wall

The heart wall comprises three distinct layers: the epicardium, myocardium, and endocardium. The outermost layer, the epicardium, is the visceral layer of the serous pericardium, featuring a thin, transparent mesothelial surface and an inner layer of areolar connective tissue with fat deposits that increase with age.
The myocardium, the thickest layer, consists of cardiac muscle cells interconnected by intercalated discs and crisscrossing connective tissue fibers. These muscle fibers contract...
5.0K
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
401